Neola’s CEO to BioStock: “The certificate is a clear sign of strength”

Neola Medical’s product Neola, developed for continuously monitoring premature infants’ lungs, has been certified according to rigorous international standards. Thus, the company has passed another milestone ahead of the US FDA application for market approval.
– This demonstrates the efficiency of our structured product development process and underlines our focus on quality and patient safety, says CEO Hanna Sjöström

Read the full interview with Hanna Sjöström at biostock.se:

https://www.biostock.se/en/2024/06/neolas-ceo-the-certificate-is-a-clear-sign-of-strength/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/